Table 3 Immunohistochemical comparison of the different markers used in the two series
IBC | Non-IBC | p value | ||
|---|---|---|---|---|
n (%) | n (%) | |||
ER | Negative | 42 (53.85%) | 99 (26.26%) | <0.001 |
Positive | 36 (46.15%) | 278 (73.74%) | ||
PR | Negative | 37 (52.86%) | 132 (35.39%) | <0.01 |
Positive | 33 (47.14%) | 241 (64.61%) | ||
ERBB2 | 0–1 | 48 (66.67%) | 301 (85.51%) | <0.001 |
2–3 | 24 (33.33%) | 51 (14.49%) | ||
EGFR | Negative | 57 (77.03%) | 240 (75.24%) | >0.05 |
Positive | 17 (22.97%) | 79 (24.76%) | ||
CK5/6 | Negative | 47 (61.04%) | 191 (67.25%) | >0.05 |
Positive | 30 (38.96%) | 93 (32.75%) | ||
CK14 | Negative | 38 (80.85%) | 295 (94.55%) | <0.01 |
Positive | 9 (19.15%) | 17 (5.45%) | ||
P-cadherin | Negative | 13 (24.07%) | 169 (51.84%) | <0.001 |
Positive | 41 (75.93%) | 157 (48.16%) | ||
P53 | Negative | 43 (58.11%) | 253 (69.7%) | >0.05 |
Positive | 31 (41.89%) | 110 (30.3%) | ||
MUC1 | Negative | 5 (6.67%) | 42 (12.84%) | >0.05 |
Positive | 70 (93.33%) | 285 (87.16%) | ||
CAV1 | Negative | 22 (31.43%) | 105 (31.16%) | >0.05 |
Positive | 48 (68.57%) | 232 (68.84%) | ||
CAV2 | Negative | 45 (90%) | 212 (89.83%) | >0.05 |
Positive | 5 (10%) | 35 (10.17%) | ||
MIB1 | ≤20 | 43 (58.9%) | 295 (87.02%) | <0.001 |
>20 | 30 (41.1%) | 44 (12.98%) |